Rein Therapeutics reports preliminary blinded Phase 2 RENEW data in idiopathic pulmonary fibrosis
Pooled, blinded data from 24 evaluable patients showed 33% improved in forced vital capacity at Week 12, though the results do not establish a treatment effect.
“Results pool LTI-03 and placebo recipients and do not establish a treatment effect.”— stock setter
Rein Therapeutics has announced preliminary blinded lung-function observations from its Phase 2 RENEW study in idiopathic pulmonary fibrosis (IPF), alongside its third-quarter 2026 financial results, according to a post on X summarising the company's announcement.
Among 24 evaluable patients, 33% improved in forced vital capacity (FVC), a measure of exhaled air volume, at Week 12. Individual changes ranged from a 338 ml improvement to a 349 ml decline. The results pool recipients of LTI-03 and placebo and do not establish a treatment effect. No serious adverse events assessed as treatment-related were reported, and 92% of patients remained on or completed the study.
Enrolment has reached 90 of approximately 120 patients. Rein expects topline results in 2027. The company reported $36.5 million in cash, cash equivalents and marketable securities, which it expects to fund operations into the first quarter of 2028.
The third-quarter net loss narrowed to $5.537 million from $5.581 million a year earlier. Research spending rose, while administrative expenses fell.
Original source
“Results pool LTI-03 and placebo recipients and do not establish a treatment effect.”
— stock setter View the post on X